CO2018006126A2 - Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadas - Google Patents
Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadasInfo
- Publication number
- CO2018006126A2 CO2018006126A2 CONC2018/0006126A CO2018006126A CO2018006126A2 CO 2018006126 A2 CO2018006126 A2 CO 2018006126A2 CO 2018006126 A CO2018006126 A CO 2018006126A CO 2018006126 A2 CO2018006126 A2 CO 2018006126A2
- Authority
- CO
- Colombia
- Prior art keywords
- kidney disease
- polycystic kidney
- biomarker
- related applications
- rpe
- Prior art date
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 abstract 2
- 102100032859 Protein AMBP Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257089P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062075 WO2017087409A1 (en) | 2015-11-18 | 2016-11-15 | Biomarker of polycystic kidney disease and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018006126A2 true CO2018006126A2 (es) | 2018-07-10 |
Family
ID=57539614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0006126A CO2018006126A2 (es) | 2015-11-18 | 2018-06-15 | Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11116755B2 (https=) |
| EP (1) | EP3377908B1 (https=) |
| JP (1) | JP6895963B2 (https=) |
| KR (1) | KR20180083902A (https=) |
| CN (1) | CN108700594B (https=) |
| AU (1) | AU2016357720A1 (https=) |
| BR (1) | BR112018009879A2 (https=) |
| CO (1) | CO2018006126A2 (https=) |
| EA (1) | EA201891170A1 (https=) |
| MX (1) | MX2018006250A (https=) |
| WO (1) | WO2017087409A1 (https=) |
| ZA (1) | ZA201803035B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018006250A (es) | 2015-11-18 | 2018-09-05 | Genzyme Corp | Biomarcador de enfermedad poliquistica renal y usos del mismo. |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
| JPWO2023145898A1 (https=) * | 2022-01-27 | 2023-08-03 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710227B1 (en) | 1998-09-16 | 2004-03-23 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| CA2256121A1 (en) | 1998-06-08 | 1999-12-08 | Hong Wang | Cyclin-dependent kinase inhibitors as plant growth regulators |
| JP4555476B2 (ja) | 1998-06-16 | 2010-09-29 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質 |
| US6559152B2 (en) | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| DE60039601D1 (de) | 1999-05-24 | 2008-09-04 | Avi Biopharma Inc | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| JP2004507455A (ja) | 2000-04-25 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途 |
| US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| EP1345941A1 (fr) | 2000-12-20 | 2003-09-24 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| AU2002365211A1 (en) | 2001-07-10 | 2003-09-02 | Bristol-Myers Squibb Pharma Company | 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| DE60313872T2 (de) | 2002-09-04 | 2008-01-17 | Schering Corp. | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ES2285164T3 (es) | 2002-09-04 | 2007-11-16 | Schering Corporation | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. |
| CA2497539A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MY141978A (en) | 2002-09-04 | 2010-08-16 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MY133311A (en) | 2002-09-19 | 2007-11-30 | Schering Corp | Novel imidazopyridines as cyclin dependent kinase inhibitors |
| AR041292A1 (es) | 2002-09-19 | 2005-05-11 | Schering Corp | Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina |
| NZ538685A (en) | 2002-09-23 | 2008-02-29 | Schering Corp | Imidazopyrazines as cyclin dependent kinase inhibitors |
| NZ538686A (en) | 2002-09-23 | 2008-01-31 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| WO2006012394A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| EP2594564B1 (en) | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| JP5661457B2 (ja) | 2007-06-06 | 2015-01-28 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | 腎疾患の予測診断 |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
| US20120077263A1 (en) | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| CA3140959A1 (en) | 2009-11-27 | 2011-06-03 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| US20110195903A1 (en) | 2009-12-15 | 2011-08-11 | Adra Chaker N | Methods and compositions for detecting recessive familial fsgs and uses thereof |
| WO2012042061A1 (en) | 2010-10-01 | 2012-04-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| US20130225443A1 (en) | 2010-11-05 | 2013-08-29 | Kyoto University | Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease |
| US20130109583A1 (en) | 2011-10-03 | 2013-05-02 | Piraye Yurttas Beim | Methods and devices for assessing risk to a putative offspring of developing a condition |
| US8961959B2 (en) | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CN102590491B (zh) * | 2012-02-06 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途 |
| WO2014006093A1 (en) | 2012-07-03 | 2014-01-09 | Boletta Alessandra | Compounds for use in polycystic kidney disease |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| RU2017106891A (ru) | 2014-08-04 | 2018-09-06 | Джензим Корпорейшн | Биомаркеры поликистозной болезни почек и пути их применения |
| MX2018006250A (es) | 2015-11-18 | 2018-09-05 | Genzyme Corp | Biomarcador de enfermedad poliquistica renal y usos del mismo. |
-
2016
- 2016-11-15 MX MX2018006250A patent/MX2018006250A/es unknown
- 2016-11-15 AU AU2016357720A patent/AU2016357720A1/en not_active Abandoned
- 2016-11-15 JP JP2018525768A patent/JP6895963B2/ja active Active
- 2016-11-15 CN CN201680079045.XA patent/CN108700594B/zh active Active
- 2016-11-15 EP EP16809582.6A patent/EP3377908B1/en active Active
- 2016-11-15 KR KR1020187016766A patent/KR20180083902A/ko not_active Withdrawn
- 2016-11-15 BR BR112018009879A patent/BR112018009879A2/pt not_active Application Discontinuation
- 2016-11-15 WO PCT/US2016/062075 patent/WO2017087409A1/en not_active Ceased
- 2016-11-15 US US15/775,736 patent/US11116755B2/en active Active
- 2016-11-15 EA EA201891170A patent/EA201891170A1/ru unknown
-
2018
- 2018-05-09 ZA ZA2018/03035A patent/ZA201803035B/en unknown
- 2018-06-15 CO CONC2018/0006126A patent/CO2018006126A2/es unknown
-
2021
- 2021-08-17 US US17/404,701 patent/US12150938B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180338961A1 (en) | 2018-11-29 |
| KR20180083902A (ko) | 2018-07-23 |
| EP3377908B1 (en) | 2020-08-05 |
| MX2018006250A (es) | 2018-09-05 |
| US12150938B2 (en) | 2024-11-26 |
| BR112018009879A2 (pt) | 2018-11-13 |
| CN108700594A (zh) | 2018-10-23 |
| ZA201803035B (en) | 2019-02-27 |
| JP6895963B2 (ja) | 2021-06-30 |
| US20210379031A1 (en) | 2021-12-09 |
| AU2016357720A1 (en) | 2018-07-05 |
| US11116755B2 (en) | 2021-09-14 |
| JP2019502902A (ja) | 2019-01-31 |
| WO2017087409A1 (en) | 2017-05-26 |
| EP3377908A1 (en) | 2018-09-26 |
| CN108700594B (zh) | 2021-06-29 |
| EA201891170A1 (ru) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| UA117364C2 (uk) | Похідні аматоксину | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| BR112017002703A2 (pt) | anticorpos específicos de mmp9. | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| CO2018006126A2 (es) | Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadas | |
| BR112018071583A2 (pt) | métodos para determinar dpp3 e métodos terapêuticos | |
| GT201800034A (es) | Anticuerpos anti-cd154 y métodos de uso de estos | |
| MX2017003387A (es) | Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico. | |
| MX375557B (es) | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer. | |
| MX2024011859A (es) | Biomarcadores de arn para angioedema hereditario | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| CO2019006234A2 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal | |
| MX2018002354A (es) | Métodos para el tratamiento de una enfermedad poliquística renal. | |
| EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
| MX381948B (es) | Composiciones y metodos para determinar el pronostico de cancer de endometrio. | |
| BR112018013807A2 (pt) | ?anticorpo anti-myl9? |